Histone deacetylases (HDACs), known for their ability to target histones as well as more than 50 non-histone proteins, are classified into three major classes according to their homology to yeast proteins, including class I (HDAC1, HDAC2, HDAC3 and HDAC8), class II (HDAC4, HDAC5, HDAC7 and HDAC9) and class IV (HDAC11). HDAC inhibitors, a large group of compounds that is able to induce the accumulation of acetylated histones as well as non-histone proteins, are divided into several structural classes including hydroxamates, cyclic peptides, aliphatic acids and benzamides. HDAC inhibitors have been investigated for their efficacy as anticancer agents in the treatment of a wild range of cancers.
Items 1-10 of 56
- C5851 MI-192Summary: inhibitor of histone deacetylases (HDACs)
- C4327 CBHASummary: HDAC inhibitor
- C4305 HNHASummary: HDAC inhibitor
- C3606 NullscriptSummary: negative control of scriptaid, HDAC inhibitor
- B5882 ORY-10011 CitationSummary: Selective inhibitor of KDM1A.
- B4988 BRD739541 CitationSummary: potent and selective HDAC inhibitor
- B4856 CAY10603Target: Histone Deacetylases (HDACs)Summary: potent and selective inhibitor of HDAC6
- B4794 Santacruzamate A (CAY10683)Target: Histone Deacetylases (HDACs)Summary: HDAC inhibitor, potent and selective
- B1251 Valproic acidTarget: Histone Deacetylases (HDACs)Summary: HDAC1 inhibitor
- B1141 Varenicline HydrochlorideSummary: α4β2 nicotinic receptor agonist